B. Kuske

发表

Fibronectin via Integrin and Decreases Attachment to In vivo Tumorigenicity Gene Expression Abolishes Ovarian Cancer

A. Paige, H. Gabra, C. Ward, 2009 .

Progressive Loss of Estrogen Receptor α Cofactor Recruitment in Endocrine Resistance

R. Clarke, D. Cameron, S. Langdon, 2007 .

Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial

A. Krause, P. Riches, Debbie Alexander, 2022, The Lancet Rheumatology.

Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup

O. Cronin, H. Harris, N. McKay, 2022, Rheumatology advances in practice.

Modification of oestrogen signalling during the acquisition of hormone resistance in breast cancer cells

B. Kuske, 2006 .

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

A. Paige, H. Gabra, C. Ward, 2009, Cancer research.

Patterns of Hamstring Muscle Tears in the General Population: A Systematic Review

A. Simpson, D. Hamilton, B. Kuske, 2016, PloS one.

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer

Liang Liang, David J Harrison, D. Cameron, 2010, Breast Cancer Research.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

R. Clarke, D. Cameron, S. Langdon, 2006, Endocrine-related cancer.

The CBETA Fractional Arc Test

B. Heltsley, J. Crittenden, D. Sagan, 2018 .

CBETA Technical Report (CBETA Note #31)

Eric Smith, Nilanjan Banerjee, Matthias Liepe, 2018 .

Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance.

R. Clarke, D. Cameron, S. Langdon, 2007, Molecular endocrinology.